QualityStocks would like to highlight
Zenosense, Inc. (
OTCQB: ZENO). The company is developing and intends to market a novel device to enable hospitals to detect Methicillin-resistant Staphylococcus Aureus (MRSA) bacterial contamination, a major constituent of Hospital Acquired Infections (HAIs). The annual costs of treating hospitalized MRSA patients are estimated to be between $3.2 billion and $4.2 billion in the United States alone. MRSA infected patients are likely to spend three times as long in a hospital stay at three times the cost, and are five times more likely to die than an uninfected patient.
In the company’s news,
Zenosense acknowledges several recent and relevant articles in the media regarding MRSA and Super-Bugs.
One such recent report comes from CBS News in which they cite a study showing MRSA is taking up residence in people’s homes as well as healthcare settings:
According to the lead researcher at Columbia University Medical Center, MRSA is now endemic in households. The findings were published on April 21, 2014 in Proceedings of the National Academy of Sciences, based on a study of 161 New York City residents who contracted MRSA infections between 2009 and 2011. It was determined that people’s homes were major reservoirs of MRSA strain USA300, which is the leading cause of community MRSA infections across the United States.
ScienceDaily has reported on an article in The New England Journal of Medicine about a new highly-resistant MRSA bacterium:
University of Texas Health Science Center in Houston’s international research team has identified this new superbug which caused a bloodstream infection in a patient in Brazil. This case is the first reported bloodstream infection caused by a highly vancomycin-resistant MRSA bacteria. Vancomycin is considered the reference standard and least expensive antibiotic used for the treatment of invasive MRSA.
U.S. News has reported on Electronic Cigarette vapor appearing to increase the virulence of MRSA:
An abstract from a study conducted by the University of California-San Diego and the VA San Diego Healthcare System claims that MRSA cells exposed to the e-cigarette vapor in the lungs of mice with pneumonia were three times more likely to survive than MRSA cells not exposed to the vapor. The lead researcher attributed the greater virulence to a change in pH, causing the MRSA bacteria to become defensive and less vulnerable to attack.
Zenosense is a detection device development company based in Valencia, Spain. Its mission is develop, market and sell an effective MRSA detector, by way of licensed-in technology, for sale to healthcare providers for use in clinical settings.
About QualityStocks
QualityStocks, based in Scottsdale, Arizona, is a free service that collects data from hundreds of Small-Cap and Micro-Cap online Investment Newsletters into one Daily Newsletter Report. QualityStocks is dedicated to assisting emerging public companies with their investor communication efforts and connecting subscribers with companies that have huge potential to succeed in the short and long-term future.
To sign up for The QualityStocks Daily Newsletter, please visit www.QualityStocks.net
To connect with QualityStocks via Facebook, please visit http://Facebook.com/QualityStocksPage
To connect with QualityStocks via Twitter, please visit http://Twitter.com/QualityStocks
Please read FULL disclaimer on the QualityStocks website: http://Disclaimer.QualityStocks.net
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company's actual results to differ materially from those indicated in any forward-looking statements.
